Ang mga Analyst ay Na-rate na Bullish, Pinansyal ay Nawasak
Pananalapi Ang mga Analyst ay Na-rate na Bullish, Pinansyal ay Nawasak 4 minuto ang nakalipas Balita ng Ethereum ng Bitcoin Revolution Medicines, Inc. (NASDAQ: RVMD) is a pharmaceutical company operating in clinical-stage precision oncology. Their focus is on creating innovative targeted therapies through the development of novel combination and monotherapy treatment regimens. The firms mission is to maximize the depth and durability of clinical benefits while also circumventing adaptive resistance mechanisms for patients who are dependent on the RAS and mTOR pathway. What Do The Research Analysts Think？ Due to the recent rise in buying volumes, Several equity researchers have recently shed light on RVMD stock price. Needham & Company LLC gave a “buy” rating during mid-September, with a price target of $34.00. Another prominent name, Stifel Nicolaus upgraded their price target from $37.00 to $47.00 and assigned a “buy” rating to the company in a research report. Taking a broader look, six analysts have assigned a “buy” rating to the company, while only one has given it a “hold” rating. The “Actual” Performance Despite the rising RVMD stock price, the company‘s performance in its quarterly reports is worsening. Since Quarter 4 of last December, the company’s revenue has been going down at a compound rate of -77%. Keeping a net
